Brind.

Tonix Pharmaceuticals CEO Buys Stock Amid Mixed Analyst Ratings

1 report, 1 independent Updated Mon 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Seth Lederman, CEO of Tonix Pharmaceuticals, made an insider purchase of company stock. Separately, research analysts have issued mixed ratings for Tonix Pharmaceuticals, including a downgrade from a “hold” to a “sell” rating by Wall Street Zen. The company recently reported revenue of $13.54 million, beating estimates, but also reported a negative return on equity of 68.99%.

From themarketsdaily.com

Why it matters

Some supportBrind's analysis of the reports

The mixed analyst coverage, which includes both a “strong-buy” rating from Raymond James Financial and a “sell” rating from Weiss Ratings, contrasts with the CEO's insider stock purchase. The consensus rating for Tonix Pharmaceuticals is currently “Buy” with a target price of $24.50.

From themarketsdaily.com

Who's involved

  • Tonix PharmaceuticalsCommercial pharmaceutical company whose stock is being rated and traded.
  • Seth LedermanChief Executive Officer of Tonix Pharmaceuticals who purchased company stock.
  • MarketBeatPersonal finance blog that covers Tonix Pharmaceuticals stock performance.

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • Tonix PharmaceuticalsSpeculative

    Analyst downgrades and mixed ratings might affect market confidence and the stock price.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped